Next Article in Journal
The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years
Previous Article in Journal
Endothelin Blockade in Diabetic Kidney Disease
Previous Article in Special Issue
Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2015, 4(6), 1193-1206; doi:10.3390/jcm4061193

The Possible Future Roles for iPSC-Derived Therapy for Autoimmune Diseases

1
Department of Clinical Immunology, Pathwest Laboratory Medicine, Queen Elizabeth II Medical Centre, Perth 6009, Western Australia, Australia
2
Department of Clinical Immunology, Royal Perth Hospital, Perth 6000, Western Australia, Australia
3
Control of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, Barcelona 08036, Spain
4
Victor Chang Cardiac Research Institute, Sydney, 2010, New South Wales, Australia
5
School of Medicine and Pharmacology, Anatomy, Physiology and Human Biology, CCTRM, University of Western Australia, Perth, 6009, Western Australia, Australia
6
School of Medicine and Pharmacology and School of Pathology and Laboratory Medicine, The University of Western Australia, Harry Perkins Institute of Medical Research, Perth, 6009, Western Australia, Australia
7
Institute for Immunology and Infectious Diseases, Murdoch University, Perth, 6150, Western Australia
*
Author to whom correspondence should be addressed.
Academic Editor: Jane Grant-Kels
Received: 31 March 2015 / Revised: 29 April 2015 / Accepted: 11 May 2015 / Published: 28 May 2015
(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)
View Full-Text   |   Download PDF [121 KB, uploaded 28 May 2015]

Abstract

The ability to generate inducible pluripotent stem cells (iPSCs) and the potential for their use in treatment of human disease is of immense interest. Autoimmune diseases, with their limited treatment choices are a potential target for the clinical application of stem cell and iPSC technology. IPSCs provide three potential ways of treating autoimmune disease; (i) providing pure replacement of lost cells (immuno-reconstitution); (ii) through immune-modulation of the disease process in vivo; and (iii) for the purposes of disease modeling in vitro. In this review, we will use examples of systemic, system-specific and organ-specific autoimmunity to explore the potential applications of iPSCs for treatment of autoimmune diseases and review the evidence of iPSC technology in auto-immunity to date. View Full-Text
Keywords: inducible; pluripotent; stem cells; autoimmunity; therapy; lupus; diabetes; multiple sclerosis inducible; pluripotent; stem cells; autoimmunity; therapy; lupus; diabetes; multiple sclerosis
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Hew, M.; O'Connor, K.; Edel, M.J.; Lucas, M. The Possible Future Roles for iPSC-Derived Therapy for Autoimmune Diseases. J. Clin. Med. 2015, 4, 1193-1206.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top